四冲IPO，屡战屡败的AI制药独角兽——英矽智能，正式进入敲钟倒计时。 在其身后，全球资本集体躬身入局！ 据不完全统计，本次英矽智能冲刺港交所，背后披露的股东多达70名左右，启明创投、高瓴资本、红杉中国等顶级投资机构抢先押注；药明康德、复星医 药、中国生物制药等产业龙头强势站台。本轮基石投资人阵容更称得上是超级豪华：15家全球顶尖机构集体入场，涵盖跨国药企礼来、新加坡主权财富基金 淡马锡、英国百年资产管理巨头施罗德、以及多家头部公募基金、险资，就连科技巨头腾讯也跨界布局。 而这场资本狂欢的盛宴，均源于四个字：AI制药。现如今，AI制药已成大势所趋，正逐渐渗透传统制药的各个环节。从2023年起，英伟达狂投十几家AI制 药公司，更将赛道热度彻底点燃。大家都在期待AI制药带来的行业颠覆，而英矽智能，早已成为这场行业颠覆中的核心焦点。 英矽智能是一家AI制药软件提供商，亦是一家AI+CRO服务商，更是一家AI赋能的创新药企业。它将候选药物从靶点发现到临床前确认的时间从传统4.5年 缩短至18个月；拿下全球前20大药企中13家的合作背书；手握超20项临床或IND阶段资产；更在商业层面，于2024年上半年交出了1085万 ...

消息面上，英国《自然》（Nature）杂志网站17日同期在线发表了由中国科研团队主导的玛仕度肽的两 项Ⅲ期临床研究成果，分别是玛仕度肽在2型糖尿病患者中的单药治疗研究（DREAMS-1）与口服降糖 药联合使用的研究（DREAMS-2）。据了解，这两项研究均基于中国患者的临床数据，由中国内分泌和 代谢领域的权威专家、科研机构和创新药企信达生物共同完成。 免责声明：以上内容为本网站转自其他媒体，相关信息仅为传递更多信息之目的，不代表本网观点，亦 不代表本网站赞同其观点或证实其内容的真实性。如稿件版权单位或个人不想在本网发布，可与本网联 系，本网视情况可立即将其撤除。 东方财富证券指出，我国创新药企业经历近十年沉淀，已过渡到管线密集收获期，2024年市场规模突破 4000亿元，"十四五"期间获批上市113个国产创新药，是"十三五"时期的2.8倍。创新药License-out项目 总金额创下新纪录，临床前项目占比达68%，显示中国创新药逐渐获得全球认可。 素材源：吕怡蕾 编辑：康书源 审核：吴娜 市场12月19日消息，今日港股市场三大指数高走，盘面上生物医药板块涨幅居前。ETF方面，截至 10:33，港股创新药ETF ...

IPO 申购指南 英矽智能(03696.HK) 建议申购 2025-12-18 星期四 【招股详情】 | 保荐人 | | | | 摩根士丹利、中金公司、广发证券 | | | | --- | --- | --- | --- | --- | --- | --- | | 上市日期 | 2025 年 | 12 | 月 30 | 日(周二) | | | | 招股价格 | 24.05 | 港元 | | | | | | 集资额 | 20.26 | | | | 亿港元（扣除包销费用和全球发售有关的估计费用） | | | 每手股数 | 500 股 | | | | | | | 入场费 | 12146 | 港元 | | | | | | 招股日期 | 2025 年 | 12 | 月 18 | 日-2025 | 12 月 23 日 | 年 | | 国元证券认购截止日期 | 2025 年 | 12 | 月 22 | 日 | | | | 招股总数 | 9469 | | | | 万股(可予调整及视乎超额配售权的行使情况而定) | | | 国际配售 | 8522 | | | | 万股(可予调整及视乎超额配售权的行使情况而定)，约占 90% | ...

Market Overview - The Chinese medical equipment market is projected to reach 1.35 trillion yuan in 2024, with an average growth rate exceeding 12% over the past decade, making it the second-largest market globally [2][6] - Shenzhen's pharmaceutical and medical device industry is expected to achieve a production value of 157.6 billion yuan in 2024, with medical devices alone surpassing 102.8 billion yuan, maintaining its position as the leading region in China for ten consecutive years [3] Industry Innovation - China is increasingly focusing on quality improvements in its medical equipment sector, with one-third of global medical equipment patents originating from the country, indicating a strengthening of domestic innovation capabilities [2][6] - Shenzhen has nurtured 35 listed companies in the pharmaceutical and medical device sectors, along with over 1,000 enterprises above designated size, showcasing a robust industrial ecosystem [3] Recent Developments - Notable recent collaborations include a 47 billion HKD (approximately 5.99 billion USD) partnership between Crystal Technology and DoveTree for AI drug development, marking a significant milestone in the commercialization of AI in pharmaceuticals [4] - Health元's innovative drug, Marpacisavir capsules, has received approval for market launch, representing a breakthrough in flu treatment with a unique mechanism requiring only one oral dose [5] Future Directions - Shenzhen aims to focus on four emerging sectors: cell and gene therapy, biomanufacturing, AI in pharmaceuticals, and health consumer products, to enhance its competitive edge in the medical equipment industry [6][7] - The establishment of an "AI + Biomanufacturing Public Service Platform" is set to accelerate the R&D cycle for biomanufacturing companies, significantly reducing development time from years to months [7]

英矽智能(3696.HK)于12月18日至12月23日正式招股，拟全球发售94,690,500股。此次招股采用机制B，香港公开发售 初始分配比例10%，不设回拨机制。每股发售价24.05港元，每手500股，一手入场费12146.27港元。预计将于12月30日 挂牌上市。 作为今年香港资本市场规模最大的Biotech IPO，英矽智能目前公布的基石投资者堪称"全明星"阵容。 英矽智能获得一众机构热捧的核心逻辑在于，2025年起Biotech融资"强者恒强"的格局。 当传统药企仍困于"十年十亿美元"的研发魔咒，AI制药同行多停留于"讲故事"和"找方向"的阶段，英矽智能四年内已 推进30多个管线，依托自有AI平台实现了持续、稳定的创新成果输出。而其核心管线ISM001-055的IIa期积极数据，更 成为AI制药领域首个药效概念验证案例。 "技术突破+临床兑现"的双重确定性使英矽智能成为资本押注AI制药的最佳标的。 礼来公司、腾讯、淡马锡、施罗德、瑞银、橡树资本、易方达、泰康人寿等15家全球顶级机构豪掷1.15亿美元认购， 这份覆盖全球制药龙头、全球互联网龙头、国际主权基金、大型资产管理公司、全球主题基金、国内龙头公 ...

英矽智能计划在本次IPO中全球发行94,690,500股。其中，香港公开发售9,469,500股，国际发售 85,221,000 股。以每股24.05港元的发行价计算，英矽智能将通过本次IPO募集至多约23亿港元，IPO市 值则将达134.06亿港元。 来源：视频滚动新闻 ...

手握全球进展最快AI药物的英矽智能(03696)于12月18日至12月23日招股。本次IPO拟发行94,690,500股 H股，其中香港公开发售占10%，国际发售占90%。每股发售价24.05港元，每手500股，一手入场费 12146.27港元。公司预期将于12月30日挂牌买卖，从募资金额上看预计将是2025年港股市场上最大的 Biotech IPO。 值得注意的是，基石投资者中礼来公司和腾讯分别代表了英矽智能所处的两大产业赛道——生物医药和 科技领域的头部力量，这也是礼来首次入局基石投资者。与此同时，本次基石投资者呈现鲜明国际化属 性，不仅资金实力雄厚，更以"长线持有、价值成长"著称。此外，英矽智能IPO前投资阵容就已十分庞 大，包括华平资本、B Capital、Prosperity7、礼来亚洲基金、百度风投、启明创投、红杉中国、药明康 德（603259）等知名机构。 英矽智能已通过自主开发的生成式人工智能平台Pharma.AI产生逾20项临床或IND申报阶段的资产，其 中三项资产已授权予国际制药及医疗保健公司，最高合约总价值20亿美元，包括总额约110.0百万美元 的预付款项以及约19亿美元的里程碑付款， ...

智通财经APP获悉，手握全球进展最快AI药物的英矽智能(03696)于12月18日至12月23日招股。本次IPO 拟发行94,690,500股H股，其中香港公开发售占10%，国际发售占90%。每股发售价24.05港元，每手500 股，一手入场费12146.27港元。公司预期将于12月30日挂牌买卖，从募资金额上看预计将是2025年港股 市场上最大的Biotech IPO。 英矽智能依托自研的Pharma.AI平台，高效搭建涵盖超过30个创新项目的管线组合，在需求广泛的肿 瘤、免疫、纤维化、代谢等领域都有涉及。据公司披露的研发数据，一款创新分子从0到1的研发耗时平 均不超过18个月，远短于传统方法(平均需时4.5年)。公司的核心资产Rentosertib(ISM001-055)也有望成 为全球首款经AI赋能发现并进入III期临床的候选药物。 商业化方面，英矽智能的业务遍及全球，全球收入最高的20家药企中13家和英矽智能有软件平台合作。 此外，英矽智能与Exelixis、美纳里尼等全球制药企业达成了3项管线授权合作，为公司带来20亿美元的 潜在收入。同时，包括赛诺菲、礼来、复星医药等在内的多家全球知名制药企业与英 ...

Core Viewpoint - The recent administrative penalty imposed on Nuotai Bio (688076.SH) due to past issues has not negatively impacted the company's current operational performance, with significant revenue and profit growth reported for the first three quarters of 2025. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 1.527 billion yuan, representing a year-on-year increase of 21.95% - The net profit attributable to shareholders reached 445 million yuan, up 26.92% year-on-year - The net profit excluding non-recurring items was 437 million yuan, reflecting a 23.20% year-on-year growth [1] Business Growth and Strategy - The company's peptide raw material drug business continues to grow significantly, driven by the expanding GLP-1 market, and is a core driver of its performance [1] - Nuotai Bio is committed to a development strategy focused on time and technology leadership, with a foundation in peptide drugs and small molecule drugs, while strategically expanding into oligonucleotide business and cutting-edge fields like synthetic biology and AI drug development [1] Innovation and R&D - The company has made a significant breakthrough in innovative R&D, with its subsidiary, Hangzhou Nuoao Biopharmaceutical Technology Co., Ltd., receiving acceptance for the clinical trial application of the new drug Semaglutide tablets, marking a milestone in oral peptide delivery technology for weight management [1] - Currently, there are no approved oral Semaglutide formulations for weight management in the domestic and international markets, indicating a substantial market opportunity for Nuotai Bio [1] Global Influence and Collaborations - Nuotai Bio has established itself as a leading enterprise in the peptide raw material drug sector, overcoming technical bottlenecks in large-scale production of long-chain peptide drugs, and is one of the few companies capable of producing over 10 kilograms of Semaglutide and other long-chain modified peptide drugs in a single batch [2] - The company has engaged in collaborations with several leading generic drug companies for the development of Semaglutide and other raw material drug projects, maintaining high growth in peptide raw material sales [2] Pipeline Development - The company has comprehensively covered its GLP-1 pipeline products, building on the success of first-generation Liraglutide, second-generation Semaglutide, and dual-target Teplizumab, while also developing a three-target Retatrutide, with an initial investment of approximately 5.08 million yuan [2] - In addition to peptide drugs, Nuotai Bio is advancing in the oligonucleotide field, with plans for commercial production capacity expected to be completed by 2025, aiming for an annual production of 1,000 kilograms of oligonucleotides and 200 kilograms of PEG-conjugated cyclic peptides [3] Strategic Partnerships - The company has formed partnerships with NuoVision and DeepTech in the areas of synthetic biology and AI empowerment, accelerating the exploration of new business fields [3] - With the gradual rollout of new production capacity and breakthroughs in cutting-edge technology, Nuotai Bio is positioned for high-quality development across multiple tracks, creating long-term value for investors [3]

Core Viewpoint - SynBioCon reports that the biomanufacturing company, Saito Bio, has announced a change in part of its fundraising investment projects, adjusting the total investment of the original project from 367 million yuan to 229 million yuan, and reallocating 124 million yuan to a new project focused on biosynthetic technology research and industrialization [3]. Group 1: Investment Project Changes - The new investment project, "Biosynthetic Technology Research and Industrialization Project," has a total investment of 237 million yuan, with the implementation led by its wholly-owned subsidiary, Jinweiduo, aiming to establish production lines for 1,000 tons/year of Tartrate Tylosin and 200 tons/year of Phosphate Tylosin [5]. - Tartrate Tylosin and Phosphate Tylosin are commonly used drugs for preventing and treating mycoplasma infections in animals, significantly reducing the incidence of respiratory diseases in livestock, indicating strong market demand [5]. Group 2: Company Background and Strategy - Established in 2010, Saito Bio was the first to utilize genetic engineering and synthetic biology for the large-scale production of steroid drug raw materials, becoming a leading supplier of steroid drug raw materials in China [5]. - In 2019, Saito Bio set a long-term industrial upgrade strategy to create a biomanufacturing enterprise integrating "pharmaceutical intermediates - active pharmaceutical ingredients - formulations," successfully producing five major steroid raw material series using synthetic biology [5]. Group 3: Strategic Collaborations - In 2024, the company formed a strategic partnership with AI pharmaceutical company, InSilico Medicine, to leverage cutting-edge AI technology and optimize key steps in the engineering transformation process for synthetic biology research and innovative drug development [6].